Galectin Therapeutics Inc. (NASDAQ: GALT) stock declined by 15.24% at the last close whereas the GALT stock price gains by 10.07% in the pre-market trading session. Galectin Therapeutics is devoted to the development of new medicines to help people with chronic liver disease and cancer live better lives.
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
Galectin Therapeutics released top-line clinical results from the extension cohort of a Phase 1b clinical study of Belapectin, a galectin-3 inhibitor, in conjunction with KEYTRUDA (pembrolizumab) in patients with metastatic melanoma and head and neck cancer1, which was begun by the investigator. Dr. Brendan D. Curti who is well-known cancer and melanoma expert is in charge of the research.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
- Looking For The Best Stocks To Buy For 2021? 3 Electric Vehicle Stocks To Watch
- Top 3 Cosmetics Stocks in the market
Nine melanoma patients and five patients with head and neck squamous cell carcinoma malignancy were recruited in the extension trial. The group in this extension trial was severely pretreated with systemic therapy, including chemotherapy, immunotherapy with checkpoint inhibitors and cytokines, melanoma mutation-directed medicines, as well as surgery and radiation therapies, relative to the initial phase 1b patients. Patients also had a high rate of metastasis, with the lungs, soft tissues, and liver being the organs most commonly affected. Four of the nine melanoma patients had choroidal tumors as their original malignancy location, as well as liver metastases.
Dr. Brendan Curti, the Principal Investigator of the study, commented,
When patients in this extension cohort were enrolled, they had a much larger tumor burden than those in the original research, which he finds promising. The extension cohort’s findings indicate the need for a Phase 2 randomized controlled trial to further examine the benefit and immunological consequences of belapectin in conjunction with KEYTRUDA vs KEYTRUDA alone and to completely demonstrate the efficacy and immunological effects of this combination.